A novel ubiquitination-based molecular signature predicts prognosis in diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma (DLBCL) exhibits significant biological heterogeneity, leading to diverse clinical outcomes. Ubiquitination, a post-translational modification process, plays a crucial regulatory role in tumor development and progression. The prognostic profile of ubiquitinated genes in DLBCL needs to be explored. We analyzed three datasets (GSE181063, GSE56315, and GSE10846) to identify ubiquitination-related survival-associated differentially expressed genes (DEGs) in DLBCL. We constructed a ubiquitination-based prognostic signature and calculated risk scores. Using R software, we investigated relationships between the identified DEGs, high- and low-risk groups, immune microenvironment, drug sensitivity, and single-cell composition. Three key ubiquitination-related survival-associated DEGs were identified: Cell Division Cycle 34 (CDC34), Fizzy-related protein homolog 1 (FZR1), and OTU Deubiquitinase with Linear Linkage Specificity (OTULIN). Elevated expression of CDC34 and FZR1, coupled with low expression of OTULIN, correlated with poor prognosis in DLBCL. These genes correlation with endocytosis-related mechanisms, T-cell, and drugs sensitive. Significant differences in immune scores and concentration for Boehringer Ingelheim compound 2536 and Osimertinib were observed between high- and low-risk groups. This study establishes a novel ubiquitination-based prognostic signature for DLBCL, offering insights into potential therapeutic targets and strategies for personalized treatment approaches.